Latest news with #AlkemLabs
Business Upturn
6 days ago
- Business
- Business Upturn
Alkem Labs shares jump 4% as Nomura maintains ‘Buy' rating with Rs 5,430 target after strong Q1 results
By Aman Shukla Published on August 13, 2025, 11:04 IST Alkem Labs shares jumped over 4% following Nomura's reaffirmation of a Buy rating with a target price of ₹5,430. As of 11:04 AM, the shares were trading 4.37% higher at Rs 5,374.00. The brokerage highlighted strong Q1 performance, where Alkem Labs exceeded expectations with sales up 4%, EBITDA soaring 25%, and net profit rising an impressive 44% compared to estimates. Alkem Labs shares showed strong performance today, trading between a low of ₹5,240 and a high of ₹5,387. The stock opened at ₹5,240, slightly higher than the previous close of ₹5,149. Over the past year, Alkem Labs has seen a 52-week low of ₹4,491.65 and a high of ₹6,439.90, indicating a solid range of movement. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
30-05-2025
- Business
- Business Upturn
Nomura maintains ‘Buy' on Alkem Labs; expects Semaglutide launch to drive future growth
By Markets Desk Published on May 30, 2025, 07:46 IST Nomura has reiterated its Buy rating on Alkem Labs with a target price of ₹5,430, viewing the Q4FY25 earnings as largely in line on sales, though EBITDA and PAT came in 2% and 6% below estimates, respectively. The company's FY26 guidance is described as a mixed bag. One key concern is an expected rise in effective tax rate (ETR) to 35–37% in FY27E, which is significantly higher than Nomura's current 20% assumption. While this will negatively impact reported earnings, cash flows remain unaffected, as cash tax will stay around 17–18%. On the operational front, domestic formulations are expected to grow ~100bps ahead of the market in FY26. The company also expects to be in the first wave of Semaglutide launches in India by March 2026, which could be a major growth driver. Disclaimer: The views and target prices mentioned in this article are as stated by Nomura. They do not represent the opinions or recommendations of this publication. Readers are advised to consult their financial advisors before making any investment decisions. Markets Desk at
